Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  ProMIS Neurosciences, Inc.    PMN   CA74346M1095

PROMIS NEUROSCIENCES, INC.

(PMN)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
03/31/2020 04/01/2020 04/02/2020 04/03/2020 04/06/2020 Date
0.125(c) 0.13(c) 0.125(c) 0.13(c) 0.13(c) Last
39 000 54 400 157 579 4 000 41 359 Volume
-3.85% +4.00% -3.85% +4.00% 0.00% Change
More quotes
Financials (CAD)
Sales 2020 -
EBIT 2020 -11,3 M
Net income 2020 -11,3 M
Debt 2020 -
Yield 2020 -
Sales 2021 -
EBIT 2021 -20,8 M
Net income 2021 -20,8 M
Debt 2021 -
Yield 2021 -
P/E ratio 2020 -4,21x
P/E ratio 2021 -2,60x
Capi. / Sales2020 -
Capi. / Sales2021 -
Capitalization 35,0 M
More Financials
Company
ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease... 
More about the company
Latest news on PROMIS NEUROSCIENCES, INC.
03/24PROMIS NEUROSCIENCES : Announces approval for warrant repricing
AQ
03/18ProMIS Neurosciences Announces Fiscal Year 2019 Annual Results
GL
02/27PROMIS NEUROSCIENCES : initiates Natural History Study of Blood-Based Biomarkers..
AQ
02/26ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarker..
GL
02/25ProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Ex..
GL
02/11ProMIS Neurosciences to Participate in Noble Capital Markets 16th Annual Inve..
GL
02/06ProMIS Neurosciences to Participate in the BIO CEO & Investor Conference
GL
01/29ProMIS Neurosciences Data for Alzheimer's Disease Program Targeting Tau Accep..
GL
01/16PROMIS NEUROSCIENCES : Appoints Dr. Jose Luis Molinuevo to its Scientific Adviso..
AQ
01/15PROMIS NEUROSCIENCES : Appoints Dr. José Luis Molinuevo to its Scientific Adviso..
PU
01/15ProMIS Neurosciences Appoints Dr. José Luis Molinuevo to its Scientific Advis..
GL
01/09ProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation F..
GL
01/08ProMIS Neurosciences issues Chairman's Update detailing positive outlook for ..
GL
01/02PROMIS NEUROSCIENCES : Completes Second Closing of Private Placement
AQ
2019PROMIS NEUROSCIENCES : Completes Second Closing of Private Placement
AQ
More news
News in other languages on PROMIS NEUROSCIENCES, INC.

- No features available -

More news
Chart PROMIS NEUROSCIENCES, INC.
Duration : Period :
ProMIS Neurosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROMIS NEUROSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 2,27  $
Last Close Price 0,09  $
Spread / Highest target 4 177%
Spread / Average Target 2 468%
Spread / Lowest Target 759%
EPS Revisions
Managers
NameTitle
Elliot Goldstein President, Chief Executive Officer & Director
Eugene Williams Executive Chairman
Daniel E. Geffken Chief Financial Officer
Neil R. Cashman Director & Chief Scientific Officer
James Kupiec Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PROMIS NEUROSCIENCES, INC.-23.53%25
GILEAD SCIENCES20.36%94 124
VERTEX PHARMACEUTICALS8.84%61 693
REGENERON PHARMACEUTICALS31.38%53 154
WUXI APPTEC CO., LTD.-0.12%21 017
GENMAB A/S-6.88%13 229